Author

C. Baquero

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:chicken / avian· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. de Dios· 1 shared A. Gutierrez-Uzquiza· 1 shared A. Lopez-Garcia· 1 shared A. M. Cuesta· 1 shared A. Porras· 1 shared A. Reyes-Palomares· 1 shared A. Vincelle-Nieto· 1 shared C. Marugan· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. de Dios

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

M. Rodrigo-Faus, A. Vincelle-Nieto, N. Vidal, J. Puente, M. Saiz-Pardo, A. Lopez-Garcia, M. Mendiburu-Elicabe, N. Palao, C. Baquero, A. M. Cuesta, H.-Q. Qu, H. Hakonarson, M. Musteanu, A. Reyes-Palomares, A. Porras, , A. Gutierrez-Uzquiza

This study identifies PRMT7 as a novel driver of metastasis in prostate cancer through CRISPR/Cas9 screens and validates its role in promoting cell motility and tumor dissemination.

bioRxiv · Jul 20, 2023 · PreprintCancer Biology

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclib.

R. Torres-Guzman, M. P. Ganado, C. Mur, C. Marugan, C. Baquero, Y. Yang, Y. Zeng, H. Bian, J. Du, A. de Dios, O. Puig, M. J. Lallena

This study shows abemaciclib, a CDK4/6 inhibitor, effectively inhibits cell proliferation and induces apoptosis with continuous treatment, outperforming other CDK4/6 inhibitors in breast cancer cell lines.

bioRxiv · Nov 15, 2021 · PreprintCell Biology